TECP
BMRN icon

Trails Edge Capital Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Trails Edge Capital Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.3M Buy
+512,000
New +$28M 4.65% 6

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Trails Edge Capital Partners's BMRN Position: Q2 2026 in Review

Trails Edge Capital Partners opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 512,000 shares worth $29.3M. The stake represents 4.65% of the portfolio and ranks #6 among its holdings.

561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Trails Edge Capital Partners held 512,000 shares of BioMarin Pharmaceuticals worth $29.3M as of Q2 2026.
  • BioMarin Pharmaceuticals was a new Trails Edge Capital Partners position in Q2 2026.
  • BioMarin Pharmaceuticals made up 4.65% of Trails Edge Capital Partners's portfolio in Q2 2026, its #6 holding.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Trails Edge Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.